CDC Updates Pneumococcal Vaccine Recommendations

Upcoming Events

KHA Workers' Compensation Fund Safety Seminar -Oct. 24-25

KHA Workers' Compensation Fund, Inc., is a taxable workers' compensation pool operated by the Kansas Health Service Corporation. This fund was formed in 1991. It is organized in accordance with the workers' compensation statutes of the State of Kansas.KHA Workers' Compensation Fund's primary objective is to provide moderately priced workers' compensation insurance to Kansas Hospital Association members. Customer service is enhanced by the Fund Administrator and Safety Program Manager.

KCHC Annual Conference - Oct. 25

In today's highly competitive and fast-changing health care world, KCHC provides members with a unique opportunity to collaborate with their peers throughout the Greater Kansas City area. Mark your calendars and plan to attend KCHC's Fall Conference on Oct. 25. Watch for additional details.

Management and Leadership Training Three-Part Webinar Series - Part 1 - Oct. 29

This webinar series is designed for all health care managers and supervisors, including those in the nursing and allied health professions who want to fine-tune their management skills.

KFMC Health Equity Summit - Oct. 30

This year’s summit will address the challenges of resource deserts and explore solutions to improve health equity in underserved communities. Don’t miss this opportunity to collaborate, learn, and drive meaningful change.

KCMHC Fall Council Meeting - Oct. 31

In February 1999, the Missouri Hospital Association and KHA formed an integrated limited liability company called The Health Alliance of MidAmerica. The Alliance enables healthcare-related organizations to strengthen efforts in the areas of policy development and federal representation and advocacy.

Current Report Articles

‹‹ Back To List

CDC Updates Pneumococcal Vaccine Recommendations

(Aug. 2, 2024) – The Centers for Disease Control and Prevention pneumococcal vaccine recommendations have been updated on June 27 to recommend PCV21 for adults. PCV21 (CAPVAXIVE, Merck) is now an option for adults aged 18 years and older who are recommended to receive a pneumococcal conjugate vaccination. Eligible individuals include those 65 years and older who have never received a PCV vaccination and individuals aged 18-64 years with underlying chronic conditions. PCV21 is an alternative to PCV20 or the PCV15+PPSV23 series. PCV21 serotypes cover ~80 percent of diagnosed invasive pneumococcal disease in adults, compared to ~60 percent covered by PCV20 (Prevnar-20, Pfizer). The CDC offers PneumoRecs VaxAdvisor as a free app to quickly and easily provide patient-specific pneumococcal vaccine guidance. There is also a web-based version that doesn't require a download.
--Karen Braman

‹‹ Back To List

Communications

Upcoming Events

Recent News